Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Frameshift variants in C10orf71 cause dilated cardiomyopathy in human, mouse, and organoid models
Yang Li, … , Wendy K. Chung, Yulin Li
Yang Li, … , Wendy K. Chung, Yulin Li
Published June 17, 2024
Citation Information: J Clin Invest. 2024;134(12):e177172. https://doi.org/10.1172/JCI177172.
View: Text | PDF
Research Article Cardiology Genetics

Frameshift variants in C10orf71 cause dilated cardiomyopathy in human, mouse, and organoid models

  • Text
  • PDF
Abstract

Research advances over the past 30 years have confirmed a critical role for genetics in the etiology of dilated cardiomyopathies (DCMs). However, full knowledge of the genetic architecture of DCM remains incomplete. We identified candidate DCM causal gene, C10orf71, in a large family with 8 patients with DCM by whole-exome sequencing. Four loss-of-function variants of C10orf71 were subsequently identified in an additional group of492 patients with sporadic DCM from 2 independent cohorts. C10orf71 was found to be an intrinsically disordered protein specifically expressed in cardiomyocytes. C10orf71-KO mice had abnormal heart morphogenesis during embryonic development and cardiac dysfunction as adults with altered expression and splicing of contractile cardiac genes. C10orf71-null cardiomyocytes exhibited impaired contractile function with unaffected sarcomere structure. Cardiomyocytes and heart organoids derived from human induced pluripotent stem cells with C10orf71 frameshift variants also had contractile defects with normal electrophysiological activity. A rescue study using a cardiac myosin activator, omecamtiv mecarbil, restored contractile function in C10orf71-KO mice. These data support C10orf71 as a causal gene for DCM by contributing to the contractile function of cardiomyocytes. Mutation-specific pathophysiology may suggest therapeutic targets and more individualized therapy.

Authors

Yang Li, Ke Ma, Zhujun Dong, Shijuan Gao, Jing Zhang, Shan Huang, Jie Yang, Guangming Fang, Yujie Li, Xiaowei Li, Carrie Welch, Emily L. Griffin, Prema Ramaswamy, Zaheer Valivullah, Xiuying Liu, Jianzeng Dong, Dao Wen Wang, Jie Du, Wendy K. Chung, Yulin Li

×

Figure 7

OM rescues cardiac contractile dysfunction caused by C10orf71 deficiency.

Options: View larger image (or click on image) Download as PowerPoint
OM rescues cardiac contractile dysfunction caused by C10orf71 deficiency...
(A) Flow chart of OM treatment and echocardiographic testing. (B–F) Echocardiographic parameters (n = 5 males and 5–6 females per group at 0, 7, 14 days after OM treatment). EF, ejection fraction; FS, fraction shortening; SV, stroke volume; LVID-s, internal dimension of left ventricle at end-systole; LVVOL-s, left ventricular volume at end-systole; LVPW-s, posterior wall thickness of LV at end-systole. *P < 0.05, ***P < 0.001 in t test. (G) A photograph of hearts from OM treated and control mice. Scale bar: 2 mm. (H) Quantification of maximum width of the hearts shown in panel G (n = 5 males per group). *P < 0.05 in Mann-Whitney test. (I) WGA staining of hearts from OM treated and control mice. Scale bar: 50 μm. (J) Quantification of cross-sectional area of CMs shown in panel I (n = 5 males per group, n = 250–300 cells per mouse). *P < 0.05, **P < 0.01 in Kruskal-Wallis combined with Dunn’s multiple comparisons test. Each dot represents 1 biological repeat. Data represent mean ± SD.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts